BACKGROUND: The use of antipsychotic therapy has been proven to have an association with the incidence of diabetes mellitus. The use of atypical antipsychotics is shown to have a higher association, in contrast with typical antipsychotics. Olanzapine and Clozapine appear to have the highest rates of diabetes mellitus incidence, due to their tendency to affect glucose metabolism compared with other antipsychotic drugs. In this research the main goal is to understand which antipsychotic drugs are the most diabetogenic and to show the mechanisms involved in the glucose metabolism dysregulations with special focus on Olanzapine considering it is a very commonly prescribed and used drug especially among patients with schizophrenia. METHODS: Our study is a literature based research. For our research we reviewed 41 Pubmed published articles from 2005 to 2015. CONCLUSION: According to most of the literature, from all the antipsychotics, Clozapine followed by Olanzapine appear to be the atypical neuroleptics that most relate to metabolic syndrome and Diabetes. The basis for this metabolic dysregulations appears to be multifactorial in origin and a result of the drugs, environment and genes interaction.

• MeSH
• antipsychotika škodlivé účinky   terapeutické užití   MeSH
• benzodiazepiny škodlivé účinky   terapeutické užití   MeSH
• diabetes mellitus 2. typu chemicky indukované   MeSH
• hodnocení rizik MeSH
• klozapin škodlivé účinky   terapeutické užití   MeSH
• lidé MeSH
• olanzapin MeSH
• schizofrenie farmakoterapie   MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• srovnávací studie MeSH
• Názvy látek
• antipsychotika MeSH
• benzodiazepiny MeSH
• klozapin MeSH
• olanzapin MeSH

Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.

• Klíčová slova
• Adipokine, Aripiprazole, Leptin, Lipid profile, PolyI:C, Schizophrenia, Wistar rats,
• MeSH
• antipsychotika škodlivé účinky   farmakologie   MeSH
• aplikace orální MeSH
• aripiprazol škodlivé účinky   farmakologie   MeSH
• cytokiny krev   MeSH
• ghrelin krev   MeSH
• glukagonu podobný peptid 1 krev   MeSH
• leptin krev   MeSH
• metabolický syndrom krev   chemicky indukované   MeSH
• modely nemocí na zvířatech MeSH
• náhodné rozdělení MeSH
• poly I-C MeSH
• potkani Wistar MeSH
• schizofrenie krev   farmakoterapie   MeSH
• tělesná hmotnost účinky léků   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antipsychotika MeSH
• aripiprazol MeSH
• cytokiny MeSH
• ghrelin MeSH
• glukagonu podobný peptid 1 MeSH
• leptin MeSH
• poly I-C MeSH